Hyderabad-based Bharat Biotech International Ltd. has set up India's only vertically integrated cell and gene therapy facility in Telangana with a total investment of over Rs 645 crore.
With this 50,000 square feet facility, the vaccine developer has forayed into cell and gene therapy and viral vector production at Genome Valley, BBIL said in a statement on Thursday.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
The investment amount will be injected in a phased manner.
The facility will help deliver targeted, life-saving treatments that address unmet clinical needs globally by concentrating on critical conditions like haematological malignancies and inherited blood disorders, it said.
"Bharat Biotech, with its extensive experience and proven excellence in viral vaccine manufacturing, is uniquely positioned to master…complexities and produce human-grade vectors at the scale and consistency needed for clinical trials, thus advancing the global fight against rare and complex diseases," its Executive Chairman Krishna Ella said.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.